
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is advancing its drug development significantly, with important milestones and data expected in 2025 and 2026, indicative of ongoing progress in treating complex conditions such as recurrent glioblastoma and leptomeningeal metastases. The company secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to support its research initiatives, which enhances its financial position and supports the viability of its treatment strategies. Additionally, the commercial launch of its assay offers an immediate revenue opportunity while solidifying Plus Therapeutics's strategic role in disease surveillance and early intervention within the clinical landscape.
Bears say
Plus Therapeutics faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its product candidates, such as rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, the company may encounter challenges in securing regulatory approval for commercial sale and obtaining suitable reimbursement for its treatments, which could further hinder revenue generation. Moreover, competition within the pharmaceutical landscape and evolving macroeconomic conditions present additional uncertainties that could adversely impact the company's financial performance.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares